Exercise amplifies cardiovascular gains from GLP-1 therapy beyond weight loss
TL;DR Summary
Nature Metabolism’s News & Views previews Sandsdal, Holt et al.’s findings that exercise alone, or in combination with the GLP-1 receptor agonist liraglutide, improves cardiovascular health markers and reduces carotid intima-media thickness. Liraglutide without exercise preserves weight loss but yields fewer cardiovascular benefits than exercise, highlighting benefits beyond weight loss for GLP-1 therapies in cardiovascular disease.
- Exercise and glucagon-like peptide 1 receptor agonists in cardiovascular disease beyond weight loss Nature
- Effects of exercise and liraglutide on vascular health and inflammation during weight loss maintenance: a prespecified secondary analysis of the S-LiTE trial Nature
- Women’s Health Wednesday: GLP-1 medication and heart health benefits NEWS10 ABC
- Exercise, not liraglutide alone, drives vascular gains after obesity-related weight loss News-Medical
- A ‘perfect storm’ for bone loss in women: Menopause and GLP-1 weight-loss drugs UCHealth
Reading Insights
Total Reads
0
Unique Readers
6
Time Saved
9 min
vs 10 min read
Condensed
97%
1,875 → 56 words
Want the full story? Read the original article
Read on Nature